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Thangam and associates [1] report the case of an unfortunate elderly male with 
history of coronary artery disease who developed an acute myocardial infarction 
due to occlusion of the right coronary artery. This was complicated by the 
development of a ventricular septal defect and refractory heart failure requiring 
implantation of cardiac devices including intra-aortic balloon pump, ventricular 
assist device (VAD) and ultimately total artificial heart (TAH). Despite all efforts, 
the patient expired ~3 months after the AMI event.  
The patient developed candidemia and retinitis attributed to cytomegalovirus 
(CMV) disease during his complicated hospital course. The authors postulate 
that these severe opportunistic infections were, in great part, a result of host 
immune defects related to VAD and TAH implantation.  
Local and systemic effects on host immune responses have been described after 
VAD implantation. Most studies were conducted in the pulsatile VAD pump era 
[2], but similar immune defects may be present with continuous flow pumps [3]. 
Dysfunctional systemic immune responses appear to be related to interactions 
between the circulating immune system and the endovascular surface of the 
implanted device. Biodegradation and leaching of device components may also 
contribute in the long-term [4]. Thus, abnormal activation of monocytes and other 
presenting cells leading to impaired phagocytic function, aberrant antigen 
presentation and excessive costimulatory signals have been described. This 
leads to aberrant activation of T cells that express CD95 and therefore become 
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more susceptible to induced cell death resulting in overall impairment of cellular 
mediated responses [2].  
VAD recipients have shown lower expression of pro-inflammatory cytokines such 
as interleukin (IL)-2, tumor necrosis factor-alpha, and higher expression of 
suppressive IL-10 and T regulatory cells during in vitro antigenic challenge, 
compared to non-VAD advanced heart failure patients [4]. Dysfunctional 
activation of B cells after VAD implantation has also been described. This may 
induce autoimmunity and production of autoantibodies [2]. Most studies of 
immune responses in VAD recipients have had important limitations including 
small samples size, cross-sectional design, suboptimal selection of control 
groups with unbalanced confounders, and lack of correlation with clinical 
outcomes. Therefore routine assessment of cellular or humoral immune 
responses or use of universal antimicrobial prophylaxis in recipients of VAD is 
not currently recommended [5].  
Overall the authors of this case report are to be commended on their effort in 
reminding us of the negative effects of VAD implantation on host immune 
responses. However, although host immune defects described in the setting of 
VAD implantation may have contributed to pathogenesis, there is a myriad of 
factors that may have increased the risk of candidemia and CMV reactivation in 
the critically-ill patient presented here.  
Examples of risk factors for candidemia in this patient include the presence of a 
central venous catheter, exposure to broad spectrum antibiotics, pancreatitis, 
prolonged stay in intensive care unit, recent abdominalthoracic surgery, among 
others. In addition, the ocular findings described as likely CMV retinitis may have 
been related to endogenous fungal endophthalmitis in the setting of candidemia, 
rather than related to CMV disease. The presence of CMV viremia is not 
surprising in this critically-ill patient and may just represent CMV reactivation not 
necessarily related to his ocular disease. For example, a recent study showed 
that the rate of detectable CMV viremia in a cohort of criticallyill septic patients 
was 24% [6]. Having said this, CMV retinitis is certainly possible, and just the 
presence of CMV viremia in critically-ill patients may be a marker of poor 
outcomes including increased 90-day mortality [6] . A pathogenic role of 
VAD/TAH implantation on CMV reactivation is plausible in this case, but the 
patient had several other factors related to his critical illness and complications 
that most likely contributed to impaired immune responses and increased risk of 
reactivation of herpes viruses such as CMV.  
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